{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T21:19:34Z","timestamp":1775855974215,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngologic Clinics of North America"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.otc.2023.02.013","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T16:34:36Z","timestamp":1680712476000},"page":"543-556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Targeted Therapies in the Treatment of Vestibular Schwannomas: Current State and New Horizons"],"prefix":"10.1016","volume":"56","author":[{"given":"D. Bradley","family":"Welling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.otc.2023.02.013_bib1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet"},{"issue":"14","key":"10.1016\/j.otc.2023.02.013_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJMra2020394","article-title":"Vestibular Schwannomas","volume":"384","author":"Carlson","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.otc.2023.02.013_bib3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.otc.2023.02.013_bib4","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.gim.2022.05.007","article-title":"Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation","volume":"24","author":"Plotkin","year":"2022","journal-title":"Genet Med"},{"issue":"6429","key":"10.1016\/j.otc.2023.02.013_bib5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/363515a0","article-title":"Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2","volume":"363","author":"Rouleau","year":"1993","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.otc.2023.02.013_bib6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","article-title":"A\u00a0novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor","volume":"72","author":"Trofatter","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.otc.2023.02.013_bib7","doi-asserted-by":"crossref","first-page":"100723","DOI":"10.1016\/j.jbior.2020.100723","article-title":"Cancer genomics of lung cancer including malignant mesothelioma: a brief overview of current status and future prospects","volume":"78","author":"Jhanwar","year":"2020","journal-title":"Adv Biol Regul"},{"issue":"6","key":"10.1016\/j.otc.2023.02.013_bib8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/138920310791824011","article-title":"Merlin, a \"magic\" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival","volume":"11","author":"Stamenkovic","year":"2010","journal-title":"Curr Protein Pept Sci"},{"issue":"9","key":"10.1016\/j.otc.2023.02.013_bib9","doi-asserted-by":"crossref","first-page":"104281","DOI":"10.1016\/j.ejmg.2021.104281","article-title":"Lessons learned from drug trials in neurofibromatosis: a systematic review","volume":"64","author":"Dhaenens","year":"2021","journal-title":"Eur J Med Genet"},{"issue":"6","key":"10.1016\/j.otc.2023.02.013_bib10","doi-asserted-by":"crossref","first-page":"e0197350","DOI":"10.1371\/journal.pone.0197350","article-title":"Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2","volume":"13","author":"Synodos for NF2 Consortium","year":"2018","journal-title":"PLoS One"},{"issue":"21 Suppl 1","key":"10.1016\/j.otc.2023.02.013_bib11","first-page":"S33","article-title":"Recommendations for imaging tumor response in neurofibromatosis clinical trials","volume":"81","author":"Dombi","year":"2013","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.otc.2023.02.013_bib12","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1158\/0008-5472.CAN-09-3107","article-title":"Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors","volume":"70","author":"Wong","year":"2010","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.otc.2023.02.013_bib13","doi-asserted-by":"crossref","first-page":"E340","DOI":"10.1002\/lary.24564","article-title":"The role of vascular endothelial growth factor and vascular stability in diseases of the ear","volume":"124","author":"London","year":"2014","journal-title":"Laryngoscope"},{"issue":"4","key":"10.1016\/j.otc.2023.02.013_bib14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"35","key":"10.1016\/j.otc.2023.02.013_bib15","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1200\/JCO.19.01367","article-title":"Multicenter, prospective, phase ii and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma","volume":"37","author":"Plotkin","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.otc.2023.02.013_bib16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/MAO.0000000000001781","article-title":"Improvement in patient-reported hearing after treatment with bevacizumab in people with neurofibromatosis type 2","volume":"39","author":"Huang","year":"2018","journal-title":"Otol Neurotol"},{"issue":"6","key":"10.1016\/j.otc.2023.02.013_bib17","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/neuonc\/noz051","article-title":"Sustained imaging response and hearing preservation with low-dose bevacizumab in sporadic vestibular schwannoma","volume":"21","author":"Karajannis","year":"2019","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.otc.2023.02.013_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2176\/nmc.oa.2019-0194","article-title":"Bevacizumab Therapy of neurofibromatosis type 2 associated vestibular schwannoma in Japanese patients","volume":"60","author":"Fujii","year":"2020","journal-title":"Neurol Med -Chir"},{"issue":"6","key":"10.1016\/j.otc.2023.02.013_bib19","doi-asserted-by":"crossref","first-page":"103148","DOI":"10.1016\/j.amjoto.2021.103148","article-title":"Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: A systematic review and meta-analysis","volume":"42","author":"Shi","year":"2021","journal-title":"Am J Otolaryngol"},{"issue":"2","key":"10.1016\/j.otc.2023.02.013_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11060-019-03234-8","article-title":"Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes","volume":"144","author":"Lu","year":"2019","journal-title":"J\u00a0Neuro Oncol"},{"issue":"14","key":"10.1016\/j.otc.2023.02.013_bib21","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","article-title":"Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas","volume":"34","author":"Blakeley","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.otc.2023.02.013_bib22","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/0194599818809085","article-title":"Bevacizumab for hearing preservation in neurofibromatosis type 2: emphasis on patient-reported outcomes and toxicities","volume":"160","author":"Sverak","year":"2019","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"5","key":"10.1016\/j.otc.2023.02.013_bib23","doi-asserted-by":"crossref","first-page":"e28228","DOI":"10.1002\/pbc.28228","article-title":"Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence","volume":"67","author":"Renzi","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.otc.2023.02.013_bib24","doi-asserted-by":"crossref","first-page":"e59941","DOI":"10.1371\/journal.pone.0059941","article-title":"Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients","volume":"8","author":"Nunes","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.otc.2023.02.013_bib25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ane.12490","article-title":"Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2","volume":"133","author":"Farschtschi","year":"2016","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"10.1016\/j.otc.2023.02.013_bib26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11060-017-2690-7","article-title":"Spinal ependymomas in NF2: a surgical disease","volume":"136","author":"Kalamarides","year":"2018","journal-title":"J\u00a0Neuro Oncol"},{"issue":"9","key":"10.1016\/j.otc.2023.02.013_bib27","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.otc.2023.02.013_bib28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s11060-018-2922-5","article-title":"Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2","volume":"139","author":"Osorio","year":"2018","journal-title":"J\u00a0Neuro Oncol"},{"issue":"2","key":"10.1016\/j.otc.2023.02.013_bib29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11060-017-2447-3","article-title":"A\u00a04-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas","volume":"133","author":"Goutagny","year":"2017","journal-title":"J\u00a0Neuro Oncol"},{"issue":"2","key":"10.1016\/j.otc.2023.02.013_bib30","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","article-title":"Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"issue":"9","key":"10.1016\/j.otc.2023.02.013_bib31","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1158\/1535-7163.MCT-21-0143","article-title":"Phase 0 clinical trial of everolimus in patients with vestibular schwannoma or meningioma","volume":"20","author":"Karajannis","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.otc.2023.02.013_bib32","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.21037\/jtd-21-195","article-title":"A\u00a0phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations","volume":"13","author":"Devarakonda","year":"2021","journal-title":"J\u00a0Thorac Dis"},{"issue":"5","key":"10.1016\/j.otc.2023.02.013_bib33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00280-020-04229-3","article-title":"A\u00a0phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies","volume":"87","author":"Collier","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.otc.2023.02.013_bib34","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/lio2.643","article-title":"Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas","volume":"6","author":"Welling","year":"2021","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"7","key":"10.1016\/j.otc.2023.02.013_bib35","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","article-title":"Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients","volume":"31","author":"Plotkin","year":"2010","journal-title":"Otol Neurotol"},{"issue":"2","key":"10.1016\/j.otc.2023.02.013_bib36","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/MAO.0b013e31823e287f","article-title":"Treatment of vestibular schwannoma cells with ErbB inhibitors","volume":"33","author":"Bush","year":"2012","journal-title":"Otol Neurotol"},{"issue":"1","key":"10.1016\/j.otc.2023.02.013_bib37","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1097\/MAO.0000000000002428","article-title":"Incidental effect of long-term tacrolimus treatment on sporadic vestibular schwannoma volume shrinkage and clinical improvement","volume":"41","author":"Delmas","year":"2020","journal-title":"Otol Neurotol"},{"issue":"22","key":"10.1016\/j.otc.2023.02.013_bib38","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-16-0569","article-title":"The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models","volume":"22","author":"Zhang","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.otc.2023.02.013_bib39","doi-asserted-by":"crossref","first-page":"e0252048","DOI":"10.1371\/journal.pone.0252048","article-title":"Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK","volume":"16","author":"Chang","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.otc.2023.02.013_bib40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10555-017-9675-z","article-title":"Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention","volume":"36","author":"Ornelas","year":"2017","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"10.1016\/j.otc.2023.02.013_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2014.12.007","article-title":"Nonsteroidal anti-inflammatory medications are cytostatic against human vestibular schwannomas","volume":"166","author":"Dilwali","year":"2015","journal-title":"Transl Res"},{"issue":"2","key":"10.1016\/j.otc.2023.02.013_bib42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00401-016-1583-8","article-title":"The importance of nerve microenvironment for schwannoma development","volume":"132","author":"Schulz","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/j.otc.2023.02.013_bib43","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MAO.0000000000000189","article-title":"Aspirin intake correlates with halted growth of sporadic vestibular schwannoma in\u00a0vivo","volume":"35","author":"Kandathil","year":"2014","journal-title":"Otol Neurotol"},{"issue":"9","key":"10.1016\/j.otc.2023.02.013_bib44","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1097\/MAO.0000000000001180","article-title":"Correlation between aspirin intake and reduced growth of human vestibular schwannoma: volumetric analysis","volume":"37","author":"Kandathil","year":"2016","journal-title":"Otol Neurotol"},{"issue":"8","key":"10.1016\/j.otc.2023.02.013_bib45","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/MAO.0000000000001506","article-title":"Vestibular schwannoma growth with aspirin and other nonsteroidal anti-inflammatory drugs","volume":"38","author":"Hunter","year":"2017","journal-title":"Otol Neurotol"},{"issue":"6","key":"10.1016\/j.otc.2023.02.013_bib46","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1177\/0194599819827812","article-title":"Impact of aspirin and other NSAID use on volumetric and linear growth in vestibular schwannoma","volume":"160","author":"Marinelli","year":"2019","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"9","key":"10.1016\/j.otc.2023.02.013_bib47","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/lary.27114","article-title":"Aspirin does not prevent growth of vestibular schwannomas: a case-control study","volume":"128","author":"MacKeith","year":"2018","journal-title":"Laryngoscope"},{"key":"10.1016\/j.otc.2023.02.013_bib48","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.12659\/MSM.903245","article-title":"Induction of mitochondrial dysfunction and oxidative damage by antibiotic drug doxycycline enhances the responsiveness of glioblastoma to chemotherapy","volume":"23","author":"Tan","year":"2017","journal-title":"Med Sci Monit"},{"issue":"12","key":"10.1016\/j.otc.2023.02.013_bib49","first-page":"1617","article-title":"Doxycycline as potential anti-cancer agent","volume":"17","author":"Ali","year":"2017","journal-title":"Anti Cancer Agents Med Chem"},{"issue":"7","key":"10.1016\/j.otc.2023.02.013_bib50","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/neuonc\/nor056","article-title":"Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2","volume":"13","author":"Ammoun","year":"2011","journal-title":"Neuro Oncol"},{"issue":"602","key":"10.1016\/j.otc.2023.02.013_bib51","doi-asserted-by":"crossref","first-page":"eabd4816","DOI":"10.1126\/scitranslmed.abd4816","article-title":"Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models","volume":"13","author":"Wu","year":"2021","journal-title":"Sci Transl Med"},{"issue":"23","key":"10.1016\/j.otc.2023.02.013_bib52","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2008.20.8355","article-title":"Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study","volume":"27","author":"Schiller","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.otc.2023.02.013_bib53","doi-asserted-by":"crossref","first-page":"E2077","DOI":"10.1073\/pnas.1719966115","article-title":"Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models","volume":"115","author":"Zhao","year":"2018","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"34","key":"10.1016\/j.otc.2023.02.013_bib54","doi-asserted-by":"crossref","first-page":"54515","DOI":"10.18632\/oncotarget.10248","article-title":"Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1","volume":"7","author":"Troutman","year":"2016","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.otc.2023.02.013_bib55","doi-asserted-by":"crossref","first-page":"31666","DOI":"10.18632\/oncotarget.15912","article-title":"Ponatinib promotes a G1 cell-cycle arrest of merlin\/NF2-deficient human schwann cells","volume":"8","author":"Petrilli","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.otc.2023.02.013_bib56","doi-asserted-by":"crossref","first-page":"890","DOI":"10.18632\/oncotarget.28254","article-title":"CUDC907, a dual phosphoinositide-3 kinase\/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells","volume":"13","author":"Huegel","year":"2022","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.otc.2023.02.013_bib57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11060-017-2567-9","article-title":"The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma","volume":"135","author":"Paldor","year":"2017","journal-title":"J\u00a0Neuro Oncol"},{"issue":"1","key":"10.1016\/j.otc.2023.02.013_bib58","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1038\/s41598-018-23609-7","article-title":"Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma","volume":"8","author":"Sagers","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.otc.2023.02.013_bib59","doi-asserted-by":"crossref","first-page":":5758","DOI":"10.1038\/s41467-019-13640-1","article-title":"A\u00a0VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2","volume":"10","author":"Tamura","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.otc.2023.02.013_bib60","doi-asserted-by":"crossref","first-page":"36215","DOI":"10.1038\/srep36215","article-title":"Sulforaphane, a natural component of broccoli, inhibits vestibular schwannoma growth in\u00a0vitro and in\u00a0vivo","volume":"6","author":"Kim","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.otc.2023.02.013_bib61","doi-asserted-by":"crossref","first-page":"698192","DOI":"10.3389\/fonc.2021.698192","article-title":"Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments","volume":"11","author":"Amaravathi","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.otc.2023.02.013_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21873\/anticanres.16127","article-title":"Effect of antibiotic treatment on attenuated salmonella typhimurium VNP20009 mediated schwannoma growth control","volume":"43","author":"Ahmed","year":"2023","journal-title":"Anticancer Res"},{"issue":"18","key":"10.1016\/j.otc.2023.02.013_bib63","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.otc.2023.02.013_bib64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14712598.2020.1725469","article-title":"Clinical development on the frontier: gene therapy for duchenne muscular dystrophy","volume":"20","author":"Asher","year":"2020","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"10.1016\/j.otc.2023.02.013_bib65","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1016\/j.ymthe.2021.03.021","article-title":"Gene therapy reforms photoreceptor structure and restores vision in NPHP5-associated Leber congenital amaurosis","volume":"29","author":"Aguirre","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.otc.2023.02.013_bib66","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.omtm.2022.06.012","article-title":"Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2","volume":"26","author":"Prabhakar","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1\u20132","key":"10.1016\/j.otc.2023.02.013_bib67","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/hum.2021.069","article-title":"The AAV9 variant capsid AAV-f mediates widespread transgene expression in nonhuman primate spinal cord after intrathecal administration","volume":"33","author":"Beharry","year":"2022","journal-title":"Hum Gene Ther"}],"container-title":["Otolaryngologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003066652300035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003066652300035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T11:56:52Z","timestamp":1710503812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003066652300035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S003066652300035X"],"URL":"https:\/\/doi.org\/10.1016\/j.otc.2023.02.013","relation":{},"ISSN":["0030-6665"],"issn-type":[{"value":"0030-6665","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Therapies in the Treatment of Vestibular Schwannomas: Current State and New Horizons","name":"articletitle","label":"Article Title"},{"value":"Otolaryngologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.otc.2023.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}